cGMP

Molecular & Metabolic Endocrinology

We are exploring new players involved in the interplay between metabolism and intracrinology. Using a mixed basic and translational approach, we are fascinated by how the complexity of phosphodiesterases and intracellular hormonal metabolism can shape adipocytes, endothelial cells, smooth muscle cells, stem cells, and cancer cells response to challenges.

Informazioni

Struttura
Spin OFF
KET
Keywords
Progetti principali
Altre informazioni

Componenti del gruppo

Nome	E-mail

Collaboratori nazionali ed internazionali

Laboratori

Pubblicazioni

Brevetti

Progetti di ricerca

ERC

ERC	Descrizione

Infrastrutture

Leggi tutto su Molecular & Metabolic Endocrinology

Phosphodiesterase inhibitors: Could they be beneficial for the treatment of COVID-19?

In March 2020, the World Health Organization declared the severe acute respiratory syndrome corona virus 2 (SARS-CoV2) infection to be a pandemic disease. SARS-CoV2 was first identified in China and, despite the restrictive measures adopted, the epidemic has spread globally, becoming a pandemic in a very short time. Though there is growing knowledge of the SARS-CoV2 infection and its clinical manifestations, an effective cure to limit its acute symptoms and its severe complications has not yet been found.

The oligomeric assembly of the phosphodiesterase-5 is a mixture of dimers and tetramers: a putative role in the regulation of function

Background: Phosphodiesterases (PDEs) are a superfamily of evolutionary conserved cyclic nucleotides (cAMP/cGMP) hydrolysing enzymes, components of transduction pathways regulating crucial aspects of cell life. PDE5, one of these families, is the molecular target of several drugs used to treat erectile dysfunction and pulmonary hypertension. Despite its medical relevance, PDE5 macromolecular structure has only been solved for the isolated regulatory and catalytic domains.